CTRI/2021/07/034522尚未招募1 期
An Open label, Multi-center, Single arm, Phase I Study to Evaluate the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of DWRX2003 (Niclosamide IM Depot Injection) following Intramuscular Administration in COVID-19 Patients
Daewoong Pharmaceutical India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Over 18 years of age, inclusive, at time of signing the Informed Consent Form (ICF)
- •2.Patients who confirm COVID-19 positive by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) assay a week prior to randomization.
- •3. Clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) or Imaging diagnosis of pneumonia plus one of the following:
- •- Respiratory rate >=24 breaths/min, or;
- •- Respiratory distress, or;
- •- SpO2 < 94% on room air
- •4. Patients who agree to give written informed consent and are willing to participate in the study.
- •5. Patients who are hospitalized or admitted to the hospital or who are planned to be.
- •6. Patients who will be available for the entire study period and is capable of understanding and communicating with the investigators and clinical study facility staff.
- •7. Female patients who are having negative results in serum pregnancy test during screening, and urine pregnancy test at randomization
- •8. Female patients of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 60 days after their dose of study treatment (Preferably two methods).
- •9. Male patient and/or Female patientâ??s partner must agree to use condoms or should have undergone vasectomy or spermicide in addition to female contraception for additional protection against conception for 60 days after their dose of study treatment (Preferably two methods).
排除标准
- •1. Patients with critical medical conditions such as:
- •A. Acute Respiratory Distress Syndrome (ARDS)
- •B. Patient who is currently in an urgent crisis where invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) is needed.
- •C. Evidence of sepsis, septic shock or multiple organ dysfunction/failure.
- •2. Patients receiving systemic corticosteroids within 15 days prior to screening
- •3. Patient who is positive or reactive for antibodies to HIV 1 and 2, hepatitis B & C, and Rapid Plasma Reagin (RPR)
- •4. Patient who is suspected to be positive for any respiratory tract viral/bacterial infection, or active tuberculosis within 14 days prior to screening.
- •5. Patient who was vaccinated (COVID-19 vaccine) prior to screening
- •6. Patients receiving or who have received antiviral therapy and anti- retroviral therapy within 28 days prior to screening visit, except patients who had stopped antiviral therapy for enough wash out period
- •7. Patient with uncontrolled respiratory disease other than COVID-19 pneumonia (i.e. Chronic Obstructive Pulmonary Disease, asthma, cystic fibrosis, etc.)
- •8. Patients with a history of uncontrolled congestive heart failure (New York Heart Association Classification of 3rd, and 4th grade), angina, myocardial infarction, cerebrovascular events, Coronary artery bypass graft (CABG), transient ischemic attack, or pulmonary embolism within 3 months to the administration of the investigational product.
- •9. Hypersensitivity to the investigational product and/or its component or emergency drugs for hypersensitivity (e.g. epinephrine).
- •10. Patient being treated for malignancy
- •11. Patient who has participated in any other clinical trial within 30 days prior to screening.
- •12. Patient who continuously requires immunosuppressants (i.e. Anti-TNFα inhibitors, interleukin inhibitors, any other immunosuppressants warranted after organ transplantation)
- •13. Patient who have blood clot disorders or bleeding tendency.
- •14. At screening, Creatinine clearance < 30 mL/min, or Estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73ã?¡ (by Cockcroft-Gault equation)
- •15. At screening, Aspartate transferase (AST) or Alanine transferase (ALT) > 5x upper limit of normal
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II study to evaluate AUTO3 in adults withDiffuse Large B Cell Lymphoma who have previously received approved treatment(s) and subsequently progressed.Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsetsMedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10036711Term: Primary mediastinal large B-cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.0Level: PTClassification code 10036710Term: Primary mediastinal large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004682-11-GBAutolus Limited171
进行中（未招募）
1 期
A Phase I/II study to evaluate AUTO3 in children and adults with acute lymphoblastic leukaemia who have previously received approved treatment(s).Acute lymphoblastic leukaemia (ALL)MedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2016-004680-39-GBAutolus Limited70
进行中（未招募）
1 期
Phase I/II study evaluating AUTO2 in patients with multiple myelomaRelapsed or Refractory Multiple MyelomaMedDRA version: 21.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864MedDRA version: 16.1 Level: HLT Classification code 10028229 Term: Multiple myelomas System Organ Class: 100000004851EUCTR2016-003893-42-GBAutolus Limited80
已完成
不适用
A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.NL-OMON47144Autolus Limited27
进行中（未招募）
1 期
Phase I/II study evaluating AUTO2 in patients with multiple myelomaRelapsed or Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864MedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851EUCTR2016-003893-42-NLAutolus Limited12